According to the FDA, the drugs are not dissolving correctly. This can impact their ability to lower a patient’s cholesterol as intended.

The court's ruling is backed by the American Medical Association, which submitted an amicus brief arguing that "scope creep" threatens patient safety. 

PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025. 

The Cardiovascular Research Foundation and Fogarty Innovation are joining forces to help innovative researchers and technologies flourish in today's competitive medtech industry. The two organizations made the partnership official at TCT 2025 in San Francisco. 

Tim Andrews, 67, is still alive and is back on the waiting list for a human donor. However, the success of his highly experimental procedure means more patients are scheduled to get genetically modified animal organs.

A new study published in JAMA, which looked at fee-for-service Medicare records from 2013–2023, found that overall participation has trended upward. However, the details paint a complicated picture.

The SELUTION SLR Drug-Eluting Balloon was the topic of two different late-breaking clinical trials at TCT 2025. Both studies found that the device was noninferior to traditional treatments after one year. Long-term data are still needed. 

The guidewire was built specifically with Medtronic's own Evolut platform in mind. However, it is also compatible with all other commercially available TAVR systems.